Max Hodak's Science Corp. is making waves in the field of neurotechnology with its ambitious plans to develop a biohybrid brain-computer interface. The company, co-founded by Hodak, a former Neuralink executive, aims to revolutionize the way we interact with our brains and potentially treat neurological disorders. With a focus on creating a biological interface between electronics and the human brain, Science Corp. is taking a unique approach that could have far-reaching implications.
One of the key figures behind this endeavor is Dr. Murat Günel, a renowned neurobiologist who has joined as a scientific advisor. His expertise in neurosurgery and brain-computer interfaces is crucial to the project's success. The goal is to surgically implant a sensor into a patient's brain, marking a significant step towards a future where lab-grown neurons and electronics work in harmony.
Science Corp. has already raised a substantial amount of funding, securing $230 million in a Series C round that valued the company at $1.5 billion. Their most advanced product, PRIMA, is designed to restore vision in patients with macular degeneration. This device has progressed through clinical trials and is set to become more widely available in Europe once regulatory approval is granted.
However, Hodak's vision goes beyond treating diseases. He envisions a future where reliable communication links between computers and the human brain can lead to human enhancement, such as acquiring new senses. This ambitious goal has driven Hodak's career, from his early days in neuroscience research to his work at Neuralink alongside Elon Musk.
The challenges in this field are not insignificant. Regulatory hurdles and the limited number of patients with applicable diagnoses have made it difficult for companies like Neuralink to establish a clear market for their devices. Hodak's decision to move away from conventional methods, such as metal probes, towards a more organic approach, is a strategic move to overcome these obstacles.
Science Corp.'s biohybrid sensor, developed under the leadership of Alan Mardinly, is a key component of their strategy. The device will be embedded with lab-grown neurons that can be stimulated with light, allowing for natural integration with the patient's brain. In 2024, the company released a working paper demonstrating the device's safety and ability to stimulate brain activity in mice.
The focus now shifts to developing prototypes and growing neuron cells for various therapeutic applications. Dr. Günel will play a pivotal role in advising the team as they prepare for human clinical trials, ensuring compliance with medical ethics boards. The initial trials will involve testing the sensor without the embedded neurons, aiming to measure brain activity without causing harm.
One of the unique aspects of Science Corp.'s approach is the placement of the sensor. Unlike Neuralink's devices, which are inserted directly into brain tissue, Science Corp.'s sensor will be implanted inside the skull but rest on top of the brain. This distinction, according to the company, eliminates the need for FDA approval, as the device poses minimal risk to patients.
The team plans to identify patient candidates who require significant brain surgery, such as stroke victims, and implant the sensor on top of their cortex. This strategy allows for the evaluation of the sensor's safety and efficacy in a real-world setting. Dr. Günel believes this device could have a profound impact on various neurological conditions, including delivering electrical stimulation to damaged brain cells and monitoring neurological activity in patients with brain tumors.
The potential of these biohybrid systems extends beyond treating diseases. Dr. Günel suggests that they could provide more effective treatments for conditions like Parkinson's disease, a progressive disorder that currently lacks reliable treatment options. By combining electronics and biological systems, the device could potentially stop the disease's progression, offering a glimmer of hope for patients.
However, the path to achieving these breakthroughs is fraught with challenges. Dr. Günel estimates that it would be optimistic to expect trials to begin in 2027, highlighting the significant amount of work that remains to be done. The journey towards a biohybrid brain-computer interface is a testament to the innovative spirit of Max Hodak and the dedicated team at Science Corp., pushing the boundaries of what's possible in neurotechnology.
